| Literature DB >> 23401755 |
Dongsheng Huang1, Rassamee Sangthong, Edward McNeil, Virasakdi Chongsuvivatwong, Weibin Zheng, Xuemei Yang.
Abstract
Background. Suboptimal adherence to antiretroviral therapy (ART) is still pervasive. The effect of using a mobile phone call intervention to improve patient adherence is currently not known. Objective. This study aims to investigate the effects of a phone call intervention on adherence to ART and quality of life (QOL) of treatment-naive and treatment-experienced patients. Methods. A randomized controlled trial was conducted in the three largest public hospitals. Adherence was measured by self-completed questionnaires. QOL was assessed by the WHOQOL-HIV BREF. Outcomes were assessed at day 15, at 1, 2, and 3 months after start of treatment for treatment-naive patients and at 3 months after study enrollment for treatment-experienced patients. Results. A total of 103 treatment-naive and 93 treatment-experienced HIV/AIDS patients were consecutively recruited. Results show that a phone call intervention could maintain high self-reported adherence among both treatment-naive and treatment-experienced patients. After three months, significant QOL improvements were observed in domains of physical health (P = 0.003), level of independence (P = 0.018), environment (P = 0.002), and spirituality/religion/personal beliefs (P = 0.021) among treatment-naive patients. Conclusion. A mobile phone call intervention to patients could maintain high adherence rates although no statistically significant differences were found. A phone call could improve some domains of QOL among treatment-naive patients.Entities:
Year: 2013 PMID: 23401755 PMCID: PMC3562599 DOI: 10.1155/2013/580974
Source DB: PubMed Journal: AIDS Res Treat ISSN: 2090-1240
Figure 1Flow chart of study participants.
Baseline characteristics of study participants in intervention and control groups.
| Participant characteristic | Treatment-naive | Treatment-experienced | ||
|---|---|---|---|---|
| Intervention ( | Control ( | Intervention ( | Control ( | |
| Sex (%) | ||||
| Male | 24 (46.2) | 27 (52.9) | 22 (47.8) | 21 (44.7) |
| Female | 28 (53.8) | 24 (47.1) | 24 (52.2) | 26 (55.3) |
| Age group (years) | ||||
| 20–40 | 38 (73.1) | 39 (76.5) | 32 (69.6) | 34 (72.3) |
| >40–60 | 14 (26.9) | 10 (19.6) | 13 (28.3) | 13 (27.6) |
| >60 | 0 (0.0) | 2 (3.9) | 1 (2.2) | 0 (0.0) |
| Ethnicity (%) | ||||
| Han | 41 (78.8) | 49 (96.1) | 41 (89.1) | 40 (85.1) |
| Other | 11 (21.2) | 2 (3.9) | 5 (10.9) | 7 (14.9) |
| Marital status (%) | ||||
| Single | 3 (5.8) | 2 (3.9) | 3 (6.5) | 2 (4.3) |
| Married/cohabiting | 44 (84.6) | 46 (90.2) | 41 (89.1) | 39 (83.0) |
| Divorced/widowed | 5 (9.6) | 3 (5.9) | 2 (4.3) | 6 (12.8) |
| Education level (%) | ||||
| None | 4 (7.7) | 3 (5.9) | 3 (6.5) | 3 (6.4) |
| Primary school | 21 (40.4) | 24 (47.1) | 14 (30.4) | 18 (38.3) |
| Junior high school | 24 (46.2) | 19 (37.3) | 22 (47.8) | 20 (42.6) |
| High school or above | 3 (5.8) | 5 (9.8) | 7 (15.2) | 6 (12.8) |
| Occupation (%) | ||||
| Agriculture | 44 (84.6) | 41 (80.4) | 37 (80.4) | 37 (78.7) |
| Business | 6 (11.5) | 7 (13.7) | 3 (6.5) | 2 (4.3) |
| Other | 2 (3.8) | 3 (5.9) | 6 (13.0) | 8 (17.0) |
| Residential area (%) | ||||
| Rural | 47 (90.4) | 48 (92.3) | 39 (84.8) | 43 (91.5) |
| Urban | 5 (9.6) | 4 (7.7) | 7 (15.2) | 4 (8.5) |
| Annual income (CNY)a | ||||
| <2000 | 22 (42.3) | 18 (35.3) | 14 (30.4) | 9 (19.1) |
| 2000–10000 | 21 (40.4) | 15 (29.4) | 24 (52.2) | 31 (66) |
| >10000 | 9 (17.3) | 18 (35.3) | 8 (17.4) | 7 (14.9) |
| Transmission route (%) | ||||
| Heterosexual | 46 (88.5) | 42 (82.4) | 43 (93.5) | 44 (93.6) |
| Injecting drug use | 6 (11.5) | 8 (15.7) | 2 (4.3) | 5 (10.6) |
| Other | 4 (7.7) | 8 (15.7) | 1 (2.2) | 1 (2.1) |
| CD4 count (cells/mm3) | ||||
| ≤100 | 12 (23.1) | 9 (17.6) | 2 (4.4) | 1 (2.2) |
| >100–200 | 13 (25.0) | 10 (19.6) | 10 (22.2) | 8 (17.8) |
| >200–350 | 27 (51.9) | 32 (62.7) | 18 (40) | 21 (46.7) |
| >350 | — | — | 15 (33.3) | 15 (33.3) |
| WHO clinical staging (%) | ||||
| I | 30 (57.7) | 36 (70.6) | 26 (56.5) | 22 (46.8) |
| II | 10 (19.2) | 6 (11.8) | 6 (13.0) | 12 (25.5) |
| ≥III or IV | 12 (23.1) | 9 (17.6) | 14 (30.4) | 13 (27.7) |
| ART regimen (%) | ||||
| AZT + 3TC + EFVb | 19 (36.5) | 15 (29.4) | 9 (19.6) | 11 (23.4) |
| AZT + 3TC + NVPc | 28 (53.8) | 31 (60.8) | 26 (56.5) | 23 (48.9) |
| Other | 5 (9.6) | 5 (9.8) | 11 (23.9) | 13 (27.7) |
a1 USD = 6.36 CNY; b,cAZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz; ART: antiretroviral therapy.
Details of the biweekly phone calls made over the 12-week study period.
| Treatment-naive patients | Treatment-experienced patients | |||||
|---|---|---|---|---|---|---|
| Phone call appointment | No. of patients requiring a phone | No. of successful calls | Call time (min) | No. of patients requiring a phone | No. of successful calls | Call time (min) |
| Day 15 | 3 | 2 (66.0) | 4.7 ± 1.2 | 46 | 32 (69.6) | 2.5 ± 2.2 |
| Month 1 | 4 | 3 (75.0) | 6.0 ± 0.0 | 46 | 30 (65.2) | 2.3 ± 2.2 |
| Month 1.5 | 51 | 46 (90.2) | 3.0 ± 1.8 | 46 | 28 (60.9) | 2.2 ± 1.2 |
| Month 2 | 6 | 2 (33.3) | 1.0 ± 1.4 | 46 | 29 (63.4) | 2.4 ± 2.1 |
| Month 2.5 | 51 | 44 (86.2) | 3.0 ± 1.8 | 46 | 29 (63.4) | 3.1 ± 1.9 |
| Month 3 | 5 | 1 (20.0) | 3.0 ± 0.0 | 6 | 6 (100.0) | 0.6 ± 1.3 |
|
| ||||||
| Overall | 120 | 98 (81.7) | 2.9 ± 1.9 | 236 | 154 (65.3) | 2.4 ± 2.0 |
Follow-up rate, self-reported adherence to treatment, CD4, and weight change between intervention and control groups over time.
| Treatment-naive patients | Treatment-experienced patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group | Group | |||||||||
|
|
| |||||||||
|
| Intervention |
| Control |
| Intervention |
| Control | |||
| Follow-up rate (%) | ||||||||||
|
| ||||||||||
| Visit 1 | 49 | 94.2 | 48 | 94.1 | 0.17 | 42 | 91.3 | 46 | 97.9 | 0.82 |
| Visit 2 | 48 | 92.3 | 47 | 92.2 | 0.20 | — | — | |||
| Visit 3 | 48 | 92.3 | 49 | 94.2 | 0.10 | — | — | |||
| Visit 4 | 47 | 90.3 | 43 | 84.3 | 0.08 | 44 | 95.7 | 44 | 93.6 | 0.66 |
|
| ||||||||||
| Self-reported adherence, mean (SD) | ||||||||||
|
| ||||||||||
| Baseline | 52 | — | 51 | — | 46 | 99.2 (2.3) | 47 | 99.1 (2.5) | 0.83 | |
| Day 15 | 40 | 98.9 (3.9) | 36 | 97.3 (11.2) | 0.98 | — | — | |||
| Month 1 | 29 | 98.7 (5.3) | 19 | 94.7 (22.5) | 0.19 | — | — | |||
| Month 2 | 32 | 99.8 (0.8) | 33 | 97.0 (17.2) | 0.98 | — | — | |||
| Month 3 | 30 | 99.7 (1.6) | 31 | 96.5 (17.8) | 0.09 | 40 | 99.6 (1.0) | 42 | 99.5 (2.0) | 0.37 |
|
| ||||||||||
| CD4 (cell count/mm3) mean (SD) | ||||||||||
|
| ||||||||||
| Baseline | 49 | 191 (99.6) | 47 | 216 (98.2) | 0.23 | 39 | 286 (129.7) | 40 | 348 (195.6) | 0.10 |
| Month 3 | 40 | 308 (124.3) | 38 | 298 (121.9) | 0.82 | 36 | 324 (125.0) | 27 | 356 (197.5) | 0.47 |
| Pre- to postchange | 40 | 111 (97.3) | 38 | 91.9 (87.8) | 0.35 | 36 | 32.1 (79.0) | 27 | 12.3 (80.3) | 0.34 |
|
| ||||||||||
| Weight (kg) mean (SD) | ||||||||||
|
| ||||||||||
| Baseline | 49 | 54.1 (8.6) | 47 | 56.7 (9.6) | 0.15 | 46 | 57.3 (9.1) | 47 | 53.4 (7.8) | 0.02 |
| Month 3 | 46 | 54.2 (9.3) | 43 | 57.3 (9.4) | 0.12 | 39 | 57.2 (9.4) | 40 | 53.3 (8.0) | 0.05 |
| Pre- to postchange | 46 | 0.9 (3.0) | 43 | 0.6 (2.3) | 0.61 | 39 | 0.2 (2.1) | 40 | 0.04 (1.8) | 0.77 |
Comparison of quality of life domains and change (mean, SD) from baseline to month 3 between intervention and control groups.
| Treatment-naive patients | Treatment-experienced patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Domain |
|
| ||||||||
|
| Intervention |
| Control |
| Intervention |
| Control | |||
| Physical well-being | ||||||||||
|
| ||||||||||
| Baseline | 52 | 12.6 ± 3.4 | 51 | 13.8 ± 2.6 | 0.044 | 46 | 14.3 ± 2.2 | 47 | 13.9 ± 2.8 | 0.478 |
| Month 3 | 30 | 16.5 ± 4.0 | 31 | 15.8 ± 3.3 | 0.414 | 40 | 16.8 ± 2.5 | 42 | 16.3 ± 2.6 | 0.319 |
| Change | 30 | 4.3 ± 3.5 | 31 | 1.5 ± 3.7 | 0.003 | 40 | 2.55 ± 3.2 | 42 | 2.38 ± 3.4 | 0.817 |
|
| ||||||||||
| Psychological status | ||||||||||
|
| ||||||||||
| Baseline | 52 | 11.7 ± 2.21 | 51 | 11.7 ± 2.2 | 0.875 | 46 | 12.1 ± 2.1 | 47 | 12.1 ± 2.0 | 0.886 |
| Month 3 | 30 | 13.3 ± 2.14 | 31 | 12.9 ± 1.9 | 0.468 | 40 | 13.9 ± 1.7 | 42 | 13.0 ± 2.4 | 0.055 |
| Change | 30 | 1.6 ± 2.37 | 31 | 1.1 ± 2.8 | 0.485 | 40 | 1.78 ± 2.4 | 42 | 0.95 ± 2.5 | 0.126 |
|
| ||||||||||
| Level of independence/work capacity | ||||||||||
|
| ||||||||||
| Baseline | 52 | 12.2 ± 2.8 | 51 | 13.2 ± 2.6 | 0.083 | 46 | 13.9 ± 2.7 | 47 | 13.1 ± 2.0 | 0.159 |
| Month 3 | 30 | 13.3 ± 2.3 | 31 | 12.9 ± 1.5 | 0.465 | 40 | 13.7 ± 1.7 | 42 | 13.0 ± 1.7 | 0.054 |
| Change | 30 | 1.4 ± 2.5 | 31 | −0.4 ± 3.2 | 0.018 | 40 | −0.2 ± 2.4 | 42 | −0.1 ± 2.1 | 0.949 |
|
| ||||||||||
| Social relationships | ||||||||||
|
| ||||||||||
| Baseline | 52 | 13.2 ± 2.3 | 51 | 13.5 ± 2.4 | 0.477 | 46 | 13.3 ± 3.1 | 47 | 13.4 ± 2.4 | 0.864 |
| Month 3 | 30 | 15.0 ± 2.2 | 31 | 14.4 ± 2.7 | 0.353 | 40 | 14.9 ± 2.2 | 42 | 14.3 ± 2.2 | 0.172 |
| Change | 30 | 1.8 ± 2.2 | 31 | 0.7 ± 3.3 | 0.114 | 40 | 1.7 ± 3.3 | 42 | 0.9 ± 2.2 | 0.214 |
|
| ||||||||||
| Environment | ||||||||||
|
| ||||||||||
| Baseline | 52 | 11.7 ± 2.2 | 51 | 12.5 ± 2.4 | 0.072 | 46 | 12.0 ± 2.5 | 47 | 12.0 ± 2.7 | 0.983 |
| Month 3 | 30 | 13.6 ± 2.2 | 31 | 12.7 ± 2.0 | 0.101 | 40 | 14.0 ± 2.3 | 42 | 13.1 ± 2.1 | 0.073 |
| Change | 30 | 1.8 ± 2.0 | 31 | −0.03 ± 2.1 | 0.002 | 40 | 2.0 ± 2.6 | 42 | 1.1 ± 2.8 | 0.135 |
|
| ||||||||||
| Spiritual/religious/personal beliefs | ||||||||||
|
| ||||||||||
| Baseline | 52 | 11.1 ± 3.5 | 51 | 12.4 ± 3.5 | 0.066 | 46 | 12.8 ± 3.7 | 47 | 12.0 ± 3.0 | 0.248 |
| Month 3 | 30 | 15.5 ± 3.0 | 31 | 14.6 ± 3.6 | 0.297 | 40 | 16.2 ± 2.9 | 42 | 15.1 ± 3.3 | 0.123 |
| Change | 30 | 4.3 ± 2.9 | 31 | 2.4 ± 3.4 | 0.021 | 40 | 3.3 ± 4.5 | 42 | 3.1 ± 4.4 | 0.836 |